Abstract
Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are an immunocompromised group who are likely to develop severe complications and mortality because of coronavirus disease 2019 (COVID-19). We report here a 61-year-old male patient of primary myelofibrosis who underwent an allo-HSCT 6 years earlier, had chronic graft-versus-host disease (cGVHD) involving the liver, lung, eyes, and skin, (with recurrent episodes of pulmonary infections) who developed severe COVID-19. The patient was treated with tocilizumab, and a combination of lopinavir/ritonavir, ribavirin, interferon-β1b. He was discharged after 31 days with full recovery. Tocilizumab, a humanized monoclonal antibody against IL6, has been shown to benefit respiratory manifestations in severe COVID19. However, this is first report, to our knowledge, of its use and benefit in a post HSCT recipient.
Keywords: GVHD; allogeneic; coronavirus disease (COVID19); stem cell transplant; tocilizumab.
【저자키워드】 Tocilizumab, Allogeneic, GVHD, coronavirus disease (COVID19), stem cell transplant, 【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, coronavirus, COVID19, Lopinavir/ritonavir, Mortality, severe COVID-19, Tocilizumab, knowledge, Lopinavir, Ritonavir, interferon, IL6, lung, pulmonary infections, ribavirin, male, Patient, Immunocompromised, Allogeneic, Hematopoietic stem cell, skin, respiratory, disease, liver, GVHD, Combination, HSCT, Graft-versus-host disease, Stem cell transplantation, stem cell, chronic graft-versus-host disease, recipients, full recovery, allogeneic hematopoietic stem cell transplantation, severe complications, eyes, recipient, respiratory manifestations, myelofibrosis, humanized monoclonal antibody, benefit, Cell, STEM, allo-HSCT, shown, develop, treated, discharged, severe complication, respiratory manifestation, 【제목키워드】 COVID19, Antiviral, clinical, Cell, chronic GVHD, Course, treated,